3rd ESTRO Forum 2015 S581 mouse IgG, PE-Cy5 labeled mouse IgG1 and PE labeled mouse IgG1. Results: Endothelial microparticles were significantly elevated in patients with HNC patients (CD31+/CD62E+/CD42b-: mean 1601±1479 EMP/µl; CD31+/CD142+/CD42b-: mean 121±135 EMP/µl) compared with control group (CD31+/CD62E+/CD42b-: mean 782±698 EMP/µl; CD31+/CD142+/CD42b-: mean 688±647 EMP/µl). The concentration of EMP were not notably increased as result of RT/RCT (CD31+/CD62E+/CD42b-: mean 1629±769; EMP/µl;CD31+/CD142+/CD42b-: mean 1257±603 EMP/µl). There were no significant differences between EMP level before treatment, one day and 3 months after radiation cessation. Furthermore, there was no significant difference in plasma EMP level in plasma of the HNC patient undergoing RT alone, RT combined with chemotherapy, postoperative RT or postoperative RCT. Conclusions: The data suggest that the release of EMP is not a marker of ECs activation as a result of early response to ionizing radiation during RT/RCT in HNC patients. Purpose/Objective: Prediction of the treatment response and overall outcome in patients is an important goal in radiation oncology. We aim to identify prognostic molecular features using gene expression profiling in gliomas. Materials and Methods: Data from [1] were used in this study. Total 152 samples including 100 glioblastomas, 21 anaplastic astrocytomas, 19 diffuse astrocytomas and 12 anaplastic oligodendrogliomas were selected for analysis and 3456 genes expressed in gliomas, including 3012 unique sequences plus an additional 444 genes from a literature survey were identified. Different from using a selected training set in [1], the total 152 samples were included in our study. Progression-free survival (PFS) period was adopted as the clinical parameter for the treatment response. Pearson's linear correlation coefficients between the gene data and PFS record were computed for selecting the candidate genes for prognosis model. Hierarchical clustering was then computed based on the expression profile of selected genes. Cox proportional hazards regression was used to calculate the hazard ratios between different groups. Results: 47 genes are selected for our prognosis model and we have 29 genes in common with results in [1] . The unsupervised hierarchical clustering allows us to cluster the 152 patients into three distinct groups based on their similarities measured over those selected 47 genes. The results of Kaplan-Meier analysis for all patients show PFS probabilities after 5 years are 70.2%, 0% and 25.7% for group 1, 2 and 3 respectively. The cox proportional hazards regression analyses show hazard ratios 23.0, 8.8 and 0.6 for group 1&2, group 1&3 and group 2&3 respectively. The same method is also applied on the non-glioblastoma patients, which are able to be clustered into two groups with PFS probabilities after 5 years 76.0% and 0% for group 1 and 2 respectively. The hazard ratio is calculated to be 25.5.
Conclusions:
In our analyses, the selected profiling results are useful in constructing a classification scheme and the unsupervised clustering method also succeeds in dividing the samples into good and poor prognosis groups. Compared with the results in [1], the good prognosis group in our result has higher PFS probabilities after 5 years and the unsupervised method is direct and easy to prevent the possible bias in the selection of training set in the supervised method. 
